

# Raymond R Townsend

List of Publications by Year  
in descending order

Source: <https://exaly.com/author-pdf/3935443/publications.pdf>

Version: 2024-02-01

246  
papers

24,439  
citations

22153  
59  
h-index

7518  
151  
g-index

257  
all docs

257  
docs citations

257  
times ranked

23627  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Association Between Socioeconomic Factors and Incident Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort (CRIC). <i>Annals of Vascular Surgery</i> , 2022, 80, 196-205.	0.9	4
2	Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis. <i>Journal of Cardiac Failure</i> , 2022, 28, 540-550.	1.7	10
3	Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 941-948.	4.7	9
4	Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. <i>Journal of Clinical Hypertension</i> , 2022, 24, 339-349.	2.0	7
5	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
6	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL). <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	18.7	114
7	Socioeconomic status impacts blood pressure response to positive airway pressure treatment. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 1287-1295.	2.6	2
8	Arterial stiffness and pulsatile hemodynamics in renal disease. , 2022, , 637-647.		0
9	Cardiovascular Implications of the 2021 KDIGO Blood Pressure Guideline for Adults With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1675-1686.	2.8	9
10	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	2.7	10
11	Renal Denervation: A Review. <i>American Journal of Kidney Diseases</i> , 2022, 80, 527-535.	1.9	11
12	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. <i>Digital Health</i> , 2022, 8, 205520762211079.	1.8	4
13	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	3.3	17
14	Orthostatic Hypertension and Intensive Blood Pressure Control; Post-Hoc Analyses of SPRINT. <i>Hypertension</i> , 2021, 77, 49-58.	2.7	13
15	Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2021, 77, 12-22.	1.9	9
16	Changes in sleepiness and 24-h blood pressure following 4 months of CPAP treatment are not mediated by ICAM-1. <i>Sleep and Breathing</i> , 2021, 25, 1495-1502.	1.7	3
17	Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. <i>American Journal of Kidney Diseases</i> , 2021, 77, 44-55.	1.9	22
18	Large Artery Stiffness: A Companion to the 2015 AHA Science Statement on Arterial Stiffness. <i>Pulse</i> , 2021, 9, 1-10.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. BMC Nephrology, 2021, 22, 69.	1.8	6
20	Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney. Journal of the American Society of Nephrology: JASN, 2021, 32, 614-627.	6.1	64
21	Imaging strategies for safety surveillance after renal artery denervation. Clinical Research in Cardiology, 2021, 110, 609-619.	3.3	4
22	Orthostatic Hypertension and Hypotension and Outcomes in CKD: The CRIC (Chronic Renal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 T	2.0	11
23	Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults. Hypertension, 2021, 77, 980-992.	2.7	11
24	Therapeutic Options to Improve Cardiovascular Outcomes with Long-Term Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 511-513.	4.5	2
25	The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort. Kidney International Reports, 2021, 6, 1066-1080.	0.8	17
26	Ambulatory and Home Blood Pressure Monitoring in Hemodialysis Patients: A Mixed-Methods Study Evaluating Comparability and Tolerability of Blood Pressure Monitoring. Kidney Medicine, 2021, 3, 457-460.	2.0	3
27	Mobile Health (mHealth) Technology: Assessment of Availability, Acceptability, and Use in CKD. American Journal of Kidney Diseases, 2021, 77, 941-950.e1.	1.9	49
28	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	2.8	63
29	Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension, 2021, 77, 2023-2033.	2.7	4
30	Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1015-1024.	4.5	7
31	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>. Catheterization and Cardiovascular Interventions, 2021, 98, 416-426.	1.7	21
32	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Journal of the American College of Cardiology, 2021, 78, 1028-1038.	2.8	27
33	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. New England Journal of Medicine, 2021, 385, 1750-1760.	27.0	142
34	A randomized trial of aerobic exercise in chronic kidney disease: Evidence for blunted cardiopulmonary adaptations. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101469.	2.3	9
35	Arterial stiffness and reference values. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 11-13.	0.6	3
36	Pathophysiology of Hypertension in Chronic Kidney Disease. , 2020, , 313-322.		1

#	ARTICLE	IF	CITATIONS
37	Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. <i>Kidney International</i> , 2020, 97, 10-13.	5.2	23
38	Systemic hemodynamic atherothrombotic syndrome (SHATS) – Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 22-32.	3.1	54
39	Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2020, 75, 394-403.	1.9	22
40	Out-of-Office Blood Pressure Monitoring: A Comparison of Ambulatory Blood Pressure Monitoring and Home (Self) Monitoring Of Blood Pressure. <i>Hypertension</i> , 2020, 76, 1667-1673.	2.7	13
41	Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2912-2923.	6.1	16
42	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2609-2621.	6.1	33
43	Conversion of Urine Protein:Creatinine Ratio or Urine Dipstick Protein to Urine Albumin:Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. <i>Annals of Internal Medicine</i> , 2020, 173, 426-435.	3.9	144
44	Health-Related Quality of Life, Depressive Symptoms, and Kidney Transplant Access in Advanced CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Kidney Medicine</i> , 2020, 2, 600-609.e1.	2.0	3
45	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	1.7	324
46	The Feasibility and Safety of Obtaining Research Kidney Biopsy Cores in Patients with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1024-1026.	4.5	10
47	Peripheral Determinants of Oxygen Utilization in Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2020, 5, 211-225.	4.1	25
48	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Trial. <i>Overlook 10</i> 1444-1451.	13.7	351
49	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1836-1846.	6.1	17
50	Norman M. Kaplan. <i>Hypertension</i> , 2020, 76, 291-293.	2.7	0
51	Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. <i>American Journal of Hypertension</i> , 2020, 33, 1003-1010.	2.0	15
52	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	3.3	28
53	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. <i>Hypertension</i> , 2020, 75, 660-667.	2.7	57
54	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 455-464.	4.5	13

#	ARTICLE	IF	CITATIONS
55	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29013-29024.	7.1	46
56	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	2.7	33
57	Evaluation of Hypertension. Nephrology Self-assessment Program: NephSAP, 2020, 19, 8-19.	3.0	2
58	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention, 2020, 16, 89-96.	3.2	59
59	Is There Any Role for Device Therapies in Resistant Hypertension? PRO. Kidney360, 2020, 1, 6-8.	2.1	0
60	Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. Journal of Clinical Hypertension, 2019, 21, 4-15.	2.0	51
61	Arterial Stiffness in CKD: A Review. American Journal of Kidney Diseases, 2019, 73, 240-247.	1.9	65
62	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension, 2019, 74, 244-249.	2.7	17
63	Renal Denervation for Treating Hypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	2.9	61
64	FP385PREDICTIVE MODELS FOR THE DEVELOPMENT OF PERIPHERAL ARTERY DISEASE AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
65	Blood pressure response to treatment of obese vs non-obese adults with sleep apnea. Journal of Clinical Hypertension, 2019, 21, 1580-1590.	2.0	7
66	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases, 2019, 74, 771-781.	1.9	11
67	Large-Artery Stiffness in Health and Disease. Journal of the American College of Cardiology, 2019, 74, 1237-1263.	2.8	512
68	Revisiting Renal Denervation. Mayo Clinic Proceedings, 2019, 94, 1665-1667.	3.0	0
69	Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research. Journal of the American College of Cardiology, 2019, 73, 317-335.	2.8	114
70	Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease. JAMA Ophthalmology, 2019, 137, 767.	2.5	28
71	Treating Hypertension Using Renal Artery Denervation: Problems and Progress. Advances in Chronic Kidney Disease, 2019, 26, 117-121.	1.4	0
72	Effects of aerobic exercise on vascular function in nondialysis chronic kidney disease: a randomized controlled trial. American Journal of Physiology - Renal Physiology, 2019, 316, F898-F905.	2.7	42

#	ARTICLE	IF	CITATIONS
73	Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension, 2019, 73, e35-e66.	2.7	740
74	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases, 2019, 73, 437-458.	1.9	24
75	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	1.9	58
76	Central Blood Pressure and Pulse Wave Velocity Changes Post Renal Denervation in Patients With Stages 3 and 4 Chronic Kidney Disease: The Regina RDN Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811982838.	1.1	8
77	Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrology, 2019, 20, 60.	1.8	37
78	The Accuracy in Measurement of Blood Pressure (AIMaBP) collaborative: Background and rationale. Journal of Clinical Hypertension, 2019, 21, 1780-1783.	2.0	16
79	Future use of the European Society of Hypertension International Protocol for validation of automated sphygmomanometers. Blood Pressure Monitoring, 2019, 24, 161-162.	0.8	6
80	Hypertension in Cancer Patients and Survivors. JACC: CardioOncology, 2019, 1, 238-251.	4.0	68
81	History and Justification of a National Blood Pressure Measurement Validated Device Listing. Hypertension, 2019, 73, 258-264.	2.7	43
82	Cardioankle vascular index and cardiovascular disease: Systematic review and metaanalysis of prospective and crosssectional studies. Journal of Clinical Hypertension, 2019, 21, 16-24.	2.0	95
83	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. European Heart Journal, 2019, 40, 743-751.	2.2	70
84	Approach to the Young Patient with New-Onset Hypertension. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 929-932.	4.5	4
85	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
86	The Value in an Ambulatory Blood-Pressure Registry. New England Journal of Medicine, 2018, 378, 1555-1556.	27.0	2
87	Systolic blood pressure as a potential target of sigma1 receptor agonist therapy. Journal of Clinical Hypertension, 2018, 20, 416-417.	2.0	4
88	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality. Hypertension, 2018, 71, 1101-1107.	2.7	99
89	2003 Mixed meal effects of neprilysin inhibition. Journal of Clinical and Translational Science, 2018, 2, 44-44.	0.6	0
90	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 2018, 138, 1602-1604.	1.6	36

#	ARTICLE	IF	CITATIONS
91	Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2859-2869.	6.1	42
92	Sleep duration and 24-hour ambulatory blood pressure in adults not on antihypertensive medications. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1712-1720.	2.0	20
93	Catheter-Based Renal Denervation for Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 93.	3.5	16
94	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet</i> , The, 2018, 391, 2346-2355.	13.7	597
95	Circulating Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Kidney Dysfunction and Arterial Stiffness. <i>American Journal of Hypertension</i> , 2018, 31, 988-994.	2.0	55
96	Cardiopulmonary exercise testing reveals subclinical abnormalities in chronic kidney disease. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1717-1724.	1.8	34
97	Hematuria as a risk factor for progression of chronic kidney disease and death: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>BMC Nephrology</i> , 2018, 19, 150.	1.8	35
98	Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	36
99	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2017, 16, 29.	6.8	80
100	Vascular Stiffness in Children With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 863-869.	2.7	27
101	Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. <i>European Heart Journal</i> , 2017, 38, 2805-2812.	2.2	175
102	A study of the VaSera arterial stiffness device in <sc>US</sc> patients. <i>Journal of Clinical Hypertension</i> , 2017, 19, 661-668.	2.0	10
103	Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1507-1515.	7.1	40
104	Blood pressure in patients with atrial fibrillation: part 2-treatment. <i>Journal of Clinical Hypertension</i> , 2017, 19, 212-214.	2.0	4
105	Blood pressure goals, variability and SGLT2 blockade in CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 75-76.	9.6	1
106	Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. <i>Circulation Research</i> , 2017, 120, 1151-1161.	4.5	52
107	<sc>Blood pressure</sc> readings using public kiosks or smart phone apps: Caveat emptor (for) Tj ETQq1 1 0.784314 rgBT /Overlock	2.0	4
108	Effect of CPAP, Weight Loss, or CPAP Plus Weight Loss on Central Hemodynamics and Arterial Stiffness. <i>Hypertension</i> , 2017, 70, 1283-1290.	2.7	10



#	ARTICLE	IF	CITATIONS
109	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. Journal of the American Society of Hypertension, 2017, 11, 783-800.	2.3	81
110	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. American Journal of Kidney Diseases, 2017, 70, 844-858.	1.9	53
111	Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1971-1978.	2.4	44
112	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. Annals of Internal Medicine, 2017, 167, 375.	3.9	78
113	Carotid Artery Wall Thickness in Obese and Nonobese Adults With Obstructive Sleep Apnea Before and Following Positive Airway Pressure Treatment. Sleep, 2017, 40, .	1.1	16
114	Medical students and measuring blood pressure: Results from the American Medical Association Blood Pressure Check Challenge. Journal of Clinical Hypertension, 2017, 19, 614-619.	2.0	54
115	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Reduction in Systolic Blood Pressure Reduction) Trial. JAMA, 2017, 317, 1476-1484.	2.7	76
116	Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis. Hypertension, 2017, 70, 435-443.	2.7	47
117	Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure. Hypertension, 2017, 69, 42-50.	2.7	143
118	Blood Pressure in Patients With Atrial Fibrillation: Part 1—Measurement. Journal of Clinical Hypertension, 2017, 19, 98-99.	2.0	9
119	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	13.7	597
120	Inflammation and Arterial Stiffness in Chronic Kidney Disease: Findings From the CRIC Study. American Journal of Hypertension, 2017, 30, 400-408.	2.0	46
121	Variants in genes belonging to the fibroblast growth factor family are associated with lower extremity amputation in non-Hispanic whites: Findings from the chronic renal insufficiency cohort study. Wound Repair and Regeneration, 2016, 24, 705-711.	3.0	1
122	Translational medicine: transforming SPRINT findings into clinical practice. Journal of the American Society of Hypertension, 2016, 10, 382-386.	2.3	6
123	Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles. Contemporary Clinical Trials Communications, 2016, 3, 70-73.	1.1	4
124	Response to Budoff and Steigerwalt. Journal of the American Society of Hypertension, 2016, 10, 470-471.	2.3	1
125	MicroRNA biomarkers in clinical renal disease: from diabetic nephropathy renal transplantation and beyond. Food and Chemical Toxicology, 2016, 98, 73-88.	3.6	28
126	Resistant Hypertension. Hypertension, 2016, 68, 1073-1080.	2.7	12



#	ARTICLE	IF	CITATIONS
127	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. American Journal of Cardiology, 2016, 118, 1855-1860.	1.6	15
128	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. American Journal of Kidney Diseases, 2016, 68, 892-900.	1.9	70
129	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney International, 2016, 90, 1348-1356.	5.2	22
130	Medication Non-Adherence: A Bigger Problem Than Physicians Assume. Journal of Clinical Hypertension, 2016, 18, 949-950.	2.0	1
131	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
132	Arterial Stiffness: Recommendations and Standardization. Pulse, 2016, 4, 3-7.	1.9	67
133	Sex Differences in the Incidence of Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S86-93.	2.2	30
134	Ankle Brachial Index and Subsequent Cardiovascular Disease Risk in Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2016, 5, .	3.7	24
135	The Associations between Peripheral Artery Disease and Physical Outcome Measures in Men and Women with Chronic Kidney Disease. Annals of Vascular Surgery, 2016, 35, 111-120.	0.9	2
136	Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. Journal of the American Society of Hypertension, 2016, 10, 224-234.e17.	2.3	68
137	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. European Journal of Cancer, 2016, 53, 96-104.	2.8	23
138	Blood Pressure Effects of Yoga, Alone or in Combination With Lifestyle Measures: Results of the Lifestyle Modification and Blood Pressure Study (<sc>LIMBS</sc>). Journal of Clinical Hypertension, 2016, 18, 809-816.	2.0	13
139	Which Patients Does the <sc>SPRINT</sc> Study <i>Not</i> Apply To and What Are the Appropriate Blood Pressure Goals in These Populations?. Journal of Clinical Hypertension, 2016, 18, 477-478.	2.0	7
140	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 642-652.	4.5	157
141	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease. Hypertension, 2016, 67, 387-396.	2.7	134
142	Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1145-1151.	0.7	41
143	American Society of Hypertension position paper: central blood pressure waveforms in health and disease. Journal of the American Society of Hypertension, 2016, 10, 22-33.	2.3	26
144	Change in Measured GFR Versus eGFR and CKD Outcomes. Journal of the American Society of Nephrology: JASN, 2016, 27, 2196-2204.	6.1	38

#	ARTICLE	IF	CITATIONS
145	Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 877-886.	6.1	71
146	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. American Heart Journal, 2016, 171, 82-91.	2.7	132
147	What Is Happening in the Area of Device-Based Blood Pressure Treatment?. Journal of Clinical Hypertension, 2016, 18, 247-247.	2.0	0
148	Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 559-569.	6.1	47
149	Blood Pressure: Definition, Diagnosis, and Management. , 2016, , 3-15.		0
150	Comparison of an in-pharmacy automated blood pressure kiosk to Daytime ambulatory blood pressure in hypertensive subjects. Journal of the American Society of Hypertension, 2015, 9, 123-129.	2.3	22
151	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. Clinical Cardiology, 2015, 38, 447-454.	1.8	9
152	Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery. Journal of Clinical Hypertension, 2015, 17, 503-513.	2.0	41
153	Role of Ambulatory and Home Blood Pressure Monitoring in Clinical Practice. Annals of Internal Medicine, 2015, 163, 691-700.	3.9	144
154	Novel Uses of Office-Based Measures of Arterial Compliance. Methodist DeBakey Cardiovascular Journal, 2015, 11, 219-222.	1.0	1
155	Should living kidney donors with hypertension be considered for organ donation?. Current Opinion in Nephrology and Hypertension, 2015, 24, 594-601.	2.0	11
156	Renal denervation for the treatment of hypertension: Making a new start, getting it right. Catheterization and Cardiovascular Interventions, 2015, 86, 855-863.	1.7	3
157	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. Annals of Internal Medicine, 2015, 162, 258-265.	3.9	128
158	Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 371-380.	1.6	251
159	Renal denervation therapy for hypertension: pathways for moving development forward. Journal of the American Society of Hypertension, 2015, 9, 341-350.	2.3	36
160	Resistive and Pulsatile Arterial Load as Predictors of Left Ventricular Mass and Geometry. Hypertension, 2015, 65, 85-92.	2.7	75
161	Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right. Journal of Clinical Hypertension, 2015, 17, 743-750.	2.0	16
162	Late Systolic Central Hypertension as a Predictor of Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2015, 4, e001335.	3.7	44

#	ARTICLE	IF	CITATIONS
163	Beyond Blood Pressure: Percutaneous Renal Denervation for the Management of Sympathetic Hyperactivity and Associated Disease States. <i>Journal of the American Heart Association</i> , 2015, 4, e001415.	3.7	14
164	Blood Pressure Targets in CKD. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 96-101.	1.4	6
165	Management of hypertension in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2015, 11, 555-563.	9.6	59
166	Investigating the Effect of Glucose on Aortic Pulse Wave Velocity Using Pancreatic Clamping Methodology. <i>Biological Research for Nursing</i> , 2015, 17, 270-275.	1.9	4
167	Proteinuria, but Not eGFR, Predicts Stroke Risk in Chronic Kidney Disease. <i>Stroke</i> , 2015, 46, 2075-2080.	2.0	70
168	A New Algorithm for the Diagnosis of Hypertension in Canada. <i>Canadian Journal of Cardiology</i> , 2015, 31, 620-630.	1.7	88
169	Arterial stiffness and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 47-53.	2.0	56
170	Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 266-273.	1.9	42
171	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1314-1321.	2.8	103
172	Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease (from the) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.65	15
173	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.8	587
174	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 769-779.	2.3	36
175	Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. <i>Hypertension</i> , 2015, 66, 698-722.	2.7	1,073
176	Ambulatory Arterial Stiffness Index and circadian blood pressure variability. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 705-710.	2.3	9
177	Chronic Renal Insufficiency Cohort Study (CRIC). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2073-2083.	4.5	87
178	Reducing Arterial Stiffness in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 547-550.	4.5	10
179	To Restrict or Not to Restrict? The Enigma of Sodium Intake and Mortality. <i>American Journal of Kidney Diseases</i> , 2015, 65, 9-11.	1.9	0
180	Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial. <i>European Heart Journal</i> , 2015, 36, 219-227.	2.2	458

#	ARTICLE	IF	CITATIONS
181	Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis. Hypertension, 2015, 65, 93-100.	2.7	122
182	SGLT2 inhibitors: their potential reduction in blood pressure. Journal of the American Society of Hypertension, 2015, 9, 48-53.	2.3	82
183	Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study. Circulation: Heart Failure, 2014, 7, 709-716.	3.9	84
184	Reflection Magnitude as a Predictor of Mortality. Hypertension, 2014, 64, 958-964.	2.7	79
185	Pathogenesis of Drug-Resistant Hypertension. Seminars in Nephrology, 2014, 34, 506-513.	1.6	16
186	Interventional management in hypertension. Current Opinion in Nephrology and Hypertension, 2014, 23, 444-448.	2.0	0
187	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.5	498
188	Serum Aldosterone and Death, End-Stage Renal Disease, and Cardiovascular Events in Blacks and Whites. Hypertension, 2014, 64, 103-110.	2.7	30
189	Increasing Use of Vitamin D Supplementation in the Chronic Renal Insufficiency Cohort Study. , 2014, 24, 186-193.		10
190	An Update on Treatment Options for Drug Resistant Hypertension. Current Cardiovascular Risk Reports, 2014, 8, 1.	2.0	0
191	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. European Heart Journal, 2014, 35, 2115-2122.	2.2	41
192	Detection, evaluation, and treatment of severe and resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, 743-757.	2.3	45
193	Home Blood Pressure Monitoring in CKD. American Journal of Kidney Diseases, 2014, 63, 835-842.	1.9	11
194	A Controlled Trial of Renal Denervation for Resistant Hypertension. New England Journal of Medicine, 2014, 370, 1393-1401.	27.0	1,848
195	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA - Journal of the American Medical Association, 2014, 311, 507.	7.4	6,625
196	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. Journal of the American College of Cardiology, 2014, 64, 1071-1078.	2.8	164
197	Top 10 landmark studies in hypertension. Journal of the American Society of Hypertension, 2014, 8, 437-447.	2.3	7
198	Retinopathy and Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1217-1224.	4.5	25

#	ARTICLE	IF	CITATIONS
199	Lifestyle Modification in Blood Pressure Study II (LIMBS): Study protocol of a randomized controlled trial assessing the efficacy of a 24week structured yoga program versus lifestyle modification on blood pressure reduction. Contemporary Clinical Trials, 2013, 36, 32-40.	1.8	6
200	Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury. Evidence-Based Medicine, 2013, 18, 232-233.	0.6	6
201	Arterial Stiffness, Kidney Function, and Chronic Kidney Disease Progression. Pulse, 2013, 1, 123-130.	1.9	14
202	Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2012, 60, 250-261.	1.9	207
203	Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. Journal of the American Society of Hypertension, 2012, 6, 309-315.	2.3	55
204	Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY HTN-3 Trial. Clinical Cardiology, 2012, 35, 528-535.	1.8	278
205	On the Waterfront. Advances in Chronic Kidney Disease, 2011, 18, 3-5.	1.4	0
206	“ROADMAP” Controversies. Journal of Clinical Hypertension, 2011, 13, 628-628.	2.0	1
207	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. Journal of Clinical Hypertension, 2011, 13, 889-897.	2.0	6
208	Attending Rounds. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2301-2306.	4.5	4
209	Central Blood Pressure and Chronic Kidney Disease Progression. International Journal of Nephrology, 2011, 2011, 1-7.	1.3	23
210	Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2612-2619.	4.5	48
211	Metabolic Syndrome, Components, and Cardiovascular Disease Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Nephrology, 2011, 33, 477-484.	3.1	29
212	Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2403-2410.	4.5	37
213	Iyengar Yoga versus Enhanced Usual Care on Blood Pressure in Patients with Prehypertension to Stage I Hypertension: a Randomized Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	1.2	59
214	Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2010, 55, 441-451.	1.9	320
215	Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. American Journal of Hypertension, 2010, 23, 282-289.	2.0	192
216	Central Pulse Pressure in Chronic Kidney Disease. Hypertension, 2010, 56, 518-524.	2.7	42

#	ARTICLE	IF	CITATIONS
217	Chronic Renal Insufficiency Cohort (CRIC) Study. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1302-1311.	4.5	497
218	Vascular Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 184-192.	4.5	218
219	Stroke in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S11-S16.	4.5	12
220	Salt intake and insulin sensitivity in healthy human volunteers. Clinical Science, 2007, 113, 141-148.	4.3	55
221	Analyzing the radial pulse waveform: narrowing the gap between blood pressure and outcomes. Current Opinion in Nephrology and Hypertension, 2007, 16, 261-266.	2.0	21
222	Finding vs Controlling Hypertensionâ€”Mind the Gap!. Journal of Clinical Hypertension, 2007, 9, 974-974.	2.0	0
223	Yoga and Hypertension. Journal of Clinical Hypertension, 2007, 9, 800-801.	2.0	12
224	Hypertensive Emergencies. , 2007, , 666-677.		0
225	Can we justify goal blood pressure of <140/90 mm hg in most hypertensives?. Current Hypertension Reports, 2005, 7, 257-264.	3.5	7
226	Sitting on the Evidence: What Is the Proper Patient Position for the Office Measurement of Blood Pressure?. Journal of Clinical Hypertension, 2005, 7, 365-366.	2.0	2
227	Of Funnel Arms, Popeye, and Otherâ€”Sized Challenges. Journal of Clinical Hypertension, 2005, 7, 755-756.	2.0	7
228	A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. American Journal of Hypertension, 2004, 17, 1056-1058.	2.0	69
229	The Forgetful Hypertensive Patient. Journal of Clinical Hypertension, 2003, 5, 89-89.	2.0	0
230	Am I More Likely to Develop Diabetes If I Have High Blood Pressure?. Journal of Clinical Hypertension, 2003, 5, 175-176.	2.0	1
231	Can I Stop Taking This Blood Pressure Medicine?. Journal of Clinical Hypertension, 2003, 5, 234-234.	2.0	0
232	Aldosterone Redux. Journal of Clinical Hypertension, 2003, 5, 300-300.	2.0	0
233	Residual Risk. Journal of Clinical Hypertension, 2003, 5, 362-363.	2.0	2
234	The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2003, 14, S148-S153.	6.1	545

#	ARTICLE	IF	CITATIONS
235	Management of Chronic Kidney Disease in an Academic Primary Care Clinic. American Journal of Nephrology, 2003, 23, 47-54.	3.1	28
236	Refractory or Resistant Hypertension. Journal of Clinical Hypertension, 2002, 4, 61-61.	2.0	0
237	Acupuncture in Hypertension. Journal of Clinical Hypertension, 2002, 4, 229-229.	2.0	0
238	Proteinuria in the Nondiabetic Hypertensive. Journal of Clinical Hypertension, 2002, 4, 309-309.	2.0	0
239	Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs. Journal of Clinical Hypertension, 2002, 4, 436-440.	2.0	1
240	Differential effect of insulin on saturated and unsaturated fatty acids. Metabolism: Clinical and Experimental, 2002, 51, 779-782.	3.4	3
241	The effects of angiotensin-II on lipolysis in humans. Metabolism: Clinical and Experimental, 2001, 50, 468-472.	3.4	29
242	Muscarinic blockade inhibits gastric emptying of mixed-nutrient meal: effects of weight and gender. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R707-R714.	1.8	28
243	Hypertension in renal failure. Disease-a-Month, 1998, 44, 243-253.	1.1	3
244	Ambulatory Blood Pressure Monitoring and Hypertensive Target Organ Damage. American Journal of the Medical Sciences, 1996, 312, 221-224.	1.1	6
245	The Role of the Renin-Angiotensin System in Insulin Sensitivity in Normotensive Subjects. American Journal of the Medical Sciences, 1993, 305, 67-71.	1.1	18
246	Combination of Converting Enzyme Inhibitor With Diuretic for the Treatment of Hypertension. Archives of Internal Medicine, 1990, 150, 1175.	3.8	66